Since December 31st, 2008, Pfizer Inc's enterprise value to ebitda (ev/ebitda) has increased from 4.24 to 5.85 at May 26th, 2023.
Pfizer Inc's enterprise value to ebitda (ev/ebitda) as of May 26th, 2023 of 5.85 was lower than its peers in the Drug Manufacturers - Major industry group of April 30th, 2023 of 228.80. From December 31st, 2008 to May 26th, 2023, Pfizer Inc's average enterprise value to ebitda (ev/ebitda) was 11.42 compared to an industry average of 2,540.15.
Pfizer, Inc. is a research-based, global biopharmaceutical company, which engages in the manufacture of vaccines and injectable biologic medicines. It operates through the following business segments: Global Innovative Pharmaceutical, Global Vaccines, Oncology and Consumer Healthcare, and Global Established Pharmaceutical. The Global Innovative Pharmaceutical segment focuses on developing, registering and commercializing novel, value creating medicines that significantly improve patients lives. The Global Vaccines, Oncology and Consumer Healthcare segment engages in the development and commercialization of vaccines and products for oncology and consumer healthcare. The Global Established Pharmaceutical segment includes the brands that have lost market exclusivity and, generally, the mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets and, to a much smaller extent, generic pharmaceuticals. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
© 2021 DiscoverCI
Disclaimer: DiscoverCI LLC is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on DiscoverCI.com represent a recommendation to buy or sell a security. The information on this site, and in its related application software, spreadsheets, blog, email and newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. In no event shall DiscoverCI.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any product, content or other material published or available on DiscoverCI.com, or relating to the use of, or inability to use, DiscoverCI.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related blog, email and newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way.